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Abstract
Despite systemic sensitization, not all allergic individuals develop asthma symptoms upon 
airborne allergen exposure. Determination of the factors that lead to the asthma phenotype in 
allergic individuals could guide treatment and identify novel therapeutic targets. In this study, we 
utilized segmental allergen challenge (SAC) of allergic asthmatics (AA) and allergic non-
asthmatic controls (AC) to determine if there are differences in the airway immune response or 
airway structural cells that could drive the development of asthma. Both groups developed 
prominent allergic airway inflammation in response to allergen. However, asthmatic subjects had 
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markedly higher levels of innate type 2 receptors on allergen-specific CD4+ T cells recruited into 
the airway. There were also increased levels of type 2 cytokines, increased total mucin and 
increased MUC5AC in response to allergen in the airways of AA subjects. Furthermore, type 2 
cytokine levels correlated with the mucin response in AA but not AC subjects, suggesting 
differences in the airway epithelial response to inflammation. Finally, AA subjects had increased 
airway smooth muscle mass at baseline measured in vivo using novel orientation-registered optical 
coherence tomography (OR-OCT). Our data demonstrate that the development of allergic asthma 
is dependent on the responsiveness of allergen-specific CD4+ T cells to innate type 2 mediators as 
well as increased sensitivity of airway epithelial cells and smooth muscle to type 2 inflammation.
Introduction
Asthma affects more than 300 million people worldwide, and most cases are allergic in 
origin (1, 2). The cardinal features of allergic asthma are eosinophilic airway inflammation, 
mucus hypersecretion and airway hyper-responsiveness (AHR) (3). Experimental evidence 
suggests that allergen-specific T helper 2 (Th2) cells and their cytokines orchestrate allergic 
airway inflammation, induce mucus production from airway epithelium and promote AHR 
(3–6). Although airway structural cells, including the epithelium and smooth muscle play an 
important role in asthma (7, 8), the link between type 2 inflammation and airway structural 
cell dysfunction is incompletely understood.
Despite systemic sensitization to airborne allergen, not all allergic individuals develop 
asthma upon allergen exposure. Many of these individuals develop asthma over time (2), 
suggesting that the pathogenic mechanisms leading to asthma may be incremental and 
potentially reversible. Thus, identification of differences in the airway response to allergen 
between allergic asthmatics (AA) and allergic non-asthmatic controls (AC) could provide 
fundamental insights into asthma pathogenesis and inform therapy. In this study, we 
performed bronchoscopic segmental allergen challenge (SAC) and characterized changes in 
airway inflammatory cells, mediators, and T cell subsets, including using class II tetramers 
to define allergen-specific CD4+ T cells. In addition, we measured mucus and airway 
smooth muscle (ASM) in vivo using optical coherence tomography (OCT) to determine 
whether structural changes correlated with type 2 inflammation. Our data suggest that 
allergic asthma results from both the allergen-specific CD4+ T cell response as well as a 
greater sensitivity of airway structural cells to type 2 inflammation.
Results
Subject characteristics
We enrolled adults with allergy to cat or dust mite to undergo bronchoscopy with SAC (9–
11). AA (n = 36) had mild asthma and evidence of AHR as defined by a positive 
methacholine challenge or bronchodilator responsiveness. AC (n = 48) had no history of 
asthma, no lower respiratory tract symptoms in response to inhaled allergen and no evidence 
of AHR. The baseline characteristics of the subjects in the two groups were well-matched 
(Supplementary Table 1). Both AA and AC had normal pulmonary function, but AA had 
lower percent predicted forced expiratory volume in 1 second (FEV1) and lower ratio of 
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FEV1 to forced vital capacity (FVC; FEV1/FVC). The threshold level of allergen sensitivity 
was determined by skin prick test titration, and the lowest concentration of extract eliciting a 
positive skin prick test was used as the allergen concentration for SAC in AA and AC 
subjects. There were no differences in number of AA and AC receiving house dust mite 
(Dermatophagoides pteronyssinus) or cat hair extract or in the median dose of allergen 
administered. For comparison, we also enrolled non-allergic healthy control (HC) subjects 
(n = 5).
Airway inflammation after SAC
Bronchoscopic SAC was performed by obtaining a baseline bronchoalveolar lavage (BAL) 
followed by administration of diluent and allergen in two separate lung subsegments. 
Twenty-four hours later, BAL was performed in the diluent- and allergen-challenged 
airways. Cell differential counts in BAL from baseline and 24 hours after SAC revealed 
eosinophilic inflammation in only the allergen-challenged segment in both AA and AC (Fig. 
1a). BAL cell counts and differentials did not differ at baseline or following diluent between 
AA and AC. In response to allergen, the number of total cells, mononuclear cells, and 
eosinophils per ml of BAL fluid increased in both AA and AC. Although there was no 
significant difference in the percentage of eosinophils from the allergen-challenged segment 
between groups, AA had a higher eosinophil count (0.72 × 106 cells/ml AA vs. 0.48 × 106 
cells/ml AC; P < 0.05). In contrast, HC did not exhibit a significant increase in total cells in 
either the diluent or allergen-challenged segment (Fig. 1a).
T cell responses to allergen
The numbers and phenotype of pro-inflammatory allergen-specific T cells and anti-
inflammatory regulatory T cells (Tregs) may determine whether allergen exposure results in 
asthma (9, 13). There were no differences in the number of CD8+ T cells, CD4+ T cells or 
Tregs at baseline between groups (Fig. 1b). Although the percentage of CD4+ T cells in the 
BAL did not change, the total number of CD4+ T cells increased similarly in both AA and 
AC following allergen challenge. The number of Tregs in the BAL fluid after allergen 
increased in AA and was higher compared to AC (0.74 × 104 cells/ml AA vs. 0.28 × 104 
cells/ml AC; P < 0.01). There was a small but non-significant increase in the number of 
Tregs in AC following allergen. There were no significant differences in the percentage of 
Tregs or in the ratio of Tregs to total CD4+ T cells between AA and AC before or after 
allergen challenge (Fig. 1b).
Treg phenotype in response to allergen
Although we observed higher numbers of Tregs in the airways of AA compared to AC, we 
reasoned that Tregs in AC may be more suppressive. Tregs can be subdivided into 
subpopulations that correlate with their suppressive capacity based on CD45RA and Foxp3 
expression, with CD45RA−Foxp3hi Tregs representing the most suppressive Tregs (Fig. 2a) 
(14). We therefore assessed the total number and distribution of Treg subpopulations in the 
BAL before and after allergen challenge in a subgroup of AA (n = 7) and AC (n = 10). The 
number of suppressive Tregs (CD45RA−Foxp3hi, group II) and non-suppressive Tregs 
(CD45RA−Foxp3int, group III) increased in response to allergen in both groups but only 
achieved statistical significance in AC. There were no significant differences between groups 
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in either the percentage or number of Treg subpopulations (Fig. 2b) or in the ratio of 
suppressive Tregs (groups I and II) to T effector and memory cells (Te+m; group IV) (Fig. 
2c). CD4+CD25high Tregs were sorted from the allergen-challenged BAL and genome-wide 
transcriptome analysis was performed (Fig. S1). There was a trend toward higher levels of 
IL-9 (P = 0.05), CTLA4, and IKZF2 (HELIOS) expression in Tregs sorted from AA after 
allergen challenge (Fig. 2d) that did not reach statistical significance after correction for 
multiple comparisons.
Characterization of allergen-specific CD4+ T cells
Although the number of CD4+ T cells was not different between AA and AC at baseline or 
following SAC, we hypothesized that there could be differences in allergen-specific CD4+ T 
cells. We used dust mite (Der p 1) and cat (Fel d 1) peptide-specific MHC class II tetramers 
to identify allergen-specific CD4+ T cells (Fig. 3a, Fig. S2 and Supplementary Table 2). 
There were very few detectable allergen-specific CD4+ T cells in the airways at baseline and 
after diluent (Fig. 3b). However, allergen-specific CD4+ T cells markedly increased in the 
airways of both AA and AC after allergen challenge (Fig. 3b). Surprisingly, there were no 
significant differences between AA and AC in the percentage or number of allergen-specific 
CD4+ T cells in the BAL under any condition examined. However, allergen-specific CD4+ T 
cells from AA had higher expression of the type 2-associated innate immune receptors 
IL-33R (ST2) (33.6% AA vs. 15.28% AC; P < 0.05) and CRTH2 (prostaglandin D2 (PGD2) 
receptor) (26.8% AA vs. 3.24% AC; P < 0.01) after allergen challenge (Fig. 3c). Moreover, 
expression of IL-33R, CRTH2, and IL-25R was enriched on allergen-specific CD4+ T cells 
compared to bulk CD4+ T cells after allergen only in AA (P < 0.01, P < 0.0001, and P < 
0.01, respectively) (Fig. 3d). No significant differences in the expression of the type 2 
chemokine receptor CCR4 were observed in either allergen-specific CD4+ T cells compared 
to bulk CD4+ T cells or between AA and AC.
Cytokine profile after allergen challenge
Inflammatory cytokines play an integral role in the pathogenesis of asthma (3, 15, 16). We 
therefore measured BAL levels of 44 cytokines and chemokines, many of which have been 
implicated in asthma pathogenesis (3, 15, 16). At baseline, AA had slightly higher absolute 
levels of IL-21, IL-33, CXCL1 and CCL21 (Fig. S3). In response to allergen, absolute levels 
of the type 2 cytokines IL-4, IL-5, IL-9, IL-13, CCL11, and CCL26, as well as the 
neutrophil-associated cytokines IL-1α, IL-1β, CXCL1 and CXCL8, were increased in AA 
compared to AC (Fig. 4a and Fig. S3). IFNγ, IL-12p40 and IL-17A were increased after 
allergen challenge in both AA and AC and were not different between groups (Fig. S3). 
Given the importance of cytokines in both initiating and propagating allergic airway 
inflammation (3, 15, 16), we examined the correlation of cytokine levels to cellular 
inflammation. Levels of IL-4, IL-5, IL-9, IL-13 and CCL26 correlated to the number of 
eosinophils in the allergen segment in both groups (Fig. 4b) and with IL-33R expression on 
allergen-specific CD4+ T cells in both groups (Fig. 4c).
We also compared the increase in cytokines after allergen challenge relative to baseline and 
diluent levels. The increase in IL-1β, IL-4, IL-5, IL-9, IL-13, IL-10, CCL11 and CCL21 in 
the allergen-challenged segment relative to baseline was higher in AA vs. AC (P < 0.05) 
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(Fig. S4a). Only the increase in IL-4, IL-9, IL-13, and IL-10 in the allergen-challenged 
segment relative to diluent was greater in AA (P < 0.05) (Fig. S4b).
Characterization of the mucin response to allergen
Increased production of mucus in the airway is a phenotypic hallmark of asthma (3). Mucins 
are the gel-forming components of airway mucus (17), and therefore we used refractometry 
(18) to measure total mucin in BAL fluid from AA, AC and HC before and after SAC. 
Baseline levels of mucin were similar in all 3 groups. Both AA and AC had a significant 
increase in mucin following allergen (7.1 μg/ml baseline vs. 52.5 μg/ml after allergen for 
AA, P < 0.0001 and 7.0 μg/ml baseline vs. 27.4 μg/ml after allergen for AC, P < 0.01; Fig. 
5a). However, AA had significantly higher levels of mucin after allergen compared to both 
AC and HC (52.5 μg/ml AA vs. 27.4 μg/ml AC vs. 6.5 μg/ml HC; P < 0.01 and P < 0.001, 
respectively). Airway mucus composition has been shown to be altered in asthmatics with 
increased levels of the gel-forming glycoprotein mucin 5AC (MUC5AC) (17, 19, 20). We 
therefore measured MUC5AC at baseline and after challenge with a mass spectrometry-
based proteomics platform. There were no differences between groups in MUC5AC levels at 
baseline. However, MUC5AC levels increased in AA BAL after allergen challenge and were 
significantly higher compared to AC (normalized spectral index 5.6 × 109 vs. 1.1 × 108, P < 
0.05) (Fig. 5b). We also performed in vivo OCT to examine whether there are differences in 
mucus quality between AA and AC. The average OCT signal intensity (pOCT) of mucus 
within the airway lumen was determined as a surrogate of particulate density (Fig. 5c) (21–
23). Mucus pOCT intensity correlated to total mucin (Fig. 5d), and at baseline AA, AC and 
HC had similar pOCT intensity (Fig. 5e). However, pOCT intensity increased after allergen 
challenge compared to baseline and diluent only in AA and was greater than pOCT intensity 
in AC and HC (81.6 AA vs 68.1 AC vs. 61.2; P < 0.05) (Fig. 5e). Furthermore, pOCT 
intensity correlated with the levels of IL-4 (R2 = 0.3802; P < 0.05) and IL-13 (R2 = 0.4656; 
P < 0.05 for both) only in AA (Fig. 5f).
Characterization of airway smooth muscle
Increased ASM mass is an important feature of airway remodeling in moderate to severe 
asthma, and it has been suggested that ASM mass increases in the setting of type 2 
inflammation (24). However, whether ASM mass increases in mild asthmatics or allergic 
non-asthmatics is unknown. We developed a novel technique to measure ASM in vivo using 
orientation-resolved OCT (OR-OCT) (see Adams, D. et al. co-submission). To determine 
whether differences in ASM mass distinguish AA from AC, we performed OR-OCT at 
baseline and measured ASM thickness and band width (Fig. 6a). AA subjects had 
significantly increased ASM thickness (70.3 μm AA vs. 35.4 μm AC vs. 35.9 μm HC; P < 
0.05 for both) and ASM band width compared to AC and HC (380.3 μm AA vs. 327.3 μm 
AC vs. 331.7 μm HC; P < 0.01 and P < 0.05, respectively) (Fig. 6b). There were no 
significant differences in ASM thickness or band width between AC and HC.
Discussion
In this study, we identified a number of novel differences in the airway immune response to 
allergen and in airway structural cells between allergic individuals with and without asthma. 
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AA had slightly higher levels of eosinophils and type 2 cytokines in the airways in response 
to allergen and a marked increase in expression of the innate type 2 receptors IL-33R and 
CRTH2 on allergen-specific CD4+ T cells compared to AC. In addition, AA had higher 
levels of mucin and qualitatively different mucus after allergen challenge. Finally, we 
measured ASM in vivo using OR-OCT and demonstrated that AA had increased ASM mass 
compared to AC.
Prior studies have documented that allergic non-asthmatics develop prominent type 2 airway 
inflammation in response to allergens despite a lack of asthma symptoms (25–33). However, 
these studies were limited by a small number of subjects, different methods for allergen 
challenge and circumscribed analyses of the immune response. In our comparatively large 
cohort, we found a greater type 2 inflammatory response to allergen in AA compared to AC, 
characterized by an increase in airway eosinophils and type 2 cytokines.
We extensively characterized the Treg response to allergen and found that AA had greater 
accumulation of Tregs in the airways after SAC. We found no differences in the numbers or 
percentage of suppressive Tregs between groups. Of interest, gene expression analysis 
suggested that AA Tregs expressed more IL-9 compared to AC Tregs. Although these 
studies may have been underpowered and require follow up, these data suggest that AA may 
have more pathogenic “Th2-type” Tregs, which have been described in a mouse model to 
express Th2-type cytokines and contribute to allergic disease (34).
One of the novel aspects of our analysis is the use of peptide:MHC class II tetramers to 
define the allergen-specific CD4+ T cell population recruited into the airways in response to 
allergen (35, 36). Using this technology, we found a marked increase in the numbers of 
allergen-specific CD4+ T cells in the BAL twenty-four hours following allergen challenge in 
both groups, suggesting recruitment of these cells into the airway.
More detailed phenotyping of T cells demonstrated enrichment of CRTH2, IL-25R and 
IL-33R-expression in allergen-specific CD4+ T cells compared to bulk CD4+ T cells only in 
AA. Importantly, allergen-specific CD4+ T cells from AA expressed higher levels of IL-33R 
and CRTH2 when compared to AC. These data suggest that AA subjects accumulate more 
Th2-polarized effector cells in the airways following allergen challenge (37). It is interesting 
to note that the levels of IL-33 in the airway at baseline were higher in AA compared to AC, 
suggesting that AA may be primed for more robust type 2 inflammation in response to 
allergen in the lung. Higher expression of IL-33R and CRTH2 on allergen-specific CD4+ T 
cells may also enhance responsiveness to type 2 signals from innate immune cells, such as 
PGD2 from mast cells and IL-33 from epithelial cells in the lung. In addition, it has recently 
been shown that IL-33 drives IL-13 expression from Th2 cells independently of the T cell 
receptor, and thus IL-33R+ CD4+ T cells may be an important source of IL-13 in allergic 
asthma (38). Furthermore, allergic asthmatics have been shown to have higher levels of 
PGD2 in the airway compared to AC in response to allergen challenge (32). Thus, our data 
suggest allergen-specific CD4+ T cells drive the development of type 2 inflammation in 
allergic individuals. Furthermore, differences in the sensitivity of allergen-specific CD4+ T 
cells to innate type 2 signals may explain the increase in eosinophils, cytokines and mucin in 
the airways of AA compared to AC.
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It is important to note however that there was considerable overlap between groups in 
measures of inflammation. Moreover, cytokine levels correlated with eosinophils and 
IL-33R expression on allergen-specific CD4+ T cells in both AA and AC. This suggests that 
there is a continuum of allergic inflammation in both groups rather than a critical threshold 
of allergic inflammation that determines the asthma phenotype. Thus, it seems unlikely that 
the magnitude of the type 2 response by itself can fully explain the dramatic phenotypic 
differences between AA and AC with respect to asthma symptoms and AHR.
Perhaps the most striking differences we observed were in the response of airway epithelium 
to allergen and in ASM. Airway epithelial cells alter both the production and composition of 
mucus in response to IL-4 and IL-13 (17, 19), and mucus hypersecretion is an important 
determinant of symptoms in asthma (17). However, the mucus response to SAC in AA and 
AC has not been previously studied. Using multiple modalities, including refractometry, 
mass spectrometry and a novel OCT-based method to measure mucus in vivo, we 
demonstrated both quantitative and qualitative differences in mucus between AA and AC. 
Although AC increased mucus production in response to allergen, it was significantly less 
than AA and not different than HC. Mucus particulate density as determined by OCT 
(pOCT) was increased following allergen challenge and correlated with IL-4 and IL-13 
levels only in AA. Furthermore, only AA had a significant increase in MUC5AC levels in 
the BAL after allergen challenge. MUC5AC is induced in epithelial cells by type-2 
cytokines and its levels are elevated in human asthma (17, 39–41). Interestingly, MUC5AC 
has also recently been shown to be required for AHR in mice (42). These results suggest that 
the airway epithelium in AA is more responsive to type 2 inflammation than in AC and 
contributes to the development of the asthma phenotype.
It is also thought that ASM contributes to AHR in asthma (5, 24). Previously, it has not been 
possible to measure ASM in vivo, and studies of ASM mass have relied on histological 
measurements. We have developed a novel OR-OCT technology (see Adams, D. et al. co-
submission) that allows for in vivo assessment of ASM. Surprisingly, we found increased 
ASM thickness and band width in AA compared to AC, even though our AA cohort had 
mild asthma and normal pulmonary function. Interestingly, differences in ASM 
measurements were observed despite significant overlap in the levels of type 2 inflammation 
observed in response to allergen in both groups and enrollment of subjects with only mild 
asthma. Our data could suggest that individuals with increased ASM are predisposed to the 
development of asthma in the setting of type 2 inflammation. Alternatively, ASM in AA may 
have increased sensitivity to type 2 inflammatory or other epithelial cell-derived signals that 
result in AHR and ASM hyperplasia and/or hypertrophy. Further studies are needed to 
define the mechanistic links between type 2 inflammation and changes in ASM mass and 
function in AA subjects.
There are several important limitations to our study that should be considered. SAC provides 
an intense and isolated allergen challenge that does not fully recapitulate aeroallergen 
exposure to the entire lung, and BAL only samples the airspaces, so cell types and mediators 
within lung tissue may not be well represented in our analyses. Furthermore, we only 
studied subjects 24 hours after challenge using just one dose of allergen based on the 
individual subject’s cutaneous “threshold” reaction. Thus, it is possible that we missed 
Cho et al. Page 7
Sci Transl Med. Author manuscript; available in PMC 2017 April 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
important differences between these groups in the initiation or resolution of inflammation 
that would be evident with different doses or at different time-points. Finally, we only 
enrolled subjects with mild asthma. Prior studies have demonstrated that the response to 
SAC is not different between mild and moderate asthmatics (43), but the response in severe 
asthmatics may be different (44, 45).
Our results suggest that type 2 airway inflammation is necessary but not sufficient for the 
allergic asthma phenotype, and that increased sensitivity of airway structural cells to type 2 
inflammation is also required. Whether structural cells in asthmatics are intrinsically more 
sensitive to type 2 inflammation or develop altered responses in the setting of chronic 
inflammation remains to be determined. Future investigations into mechanisms that 
determine responsiveness of airway structural cells to allergen and type 2 inflammation may 
reveal important new therapeutic targets for asthma that can alter the course of this chronic 
disease.
Materials and Methods
Study Design
The primary aims of this study were to compare the immune and airway response to 
segmental allergen challenge (SAC) in aeroallergen allergic subjects with asthma (AA) and 
without asthma (AC). A group of healthy controls (HC) was also included. Participants were 
recruited via advertisement in the Massachusetts General Hospital outpatient clinics and 
around the Boston metropolitan area. Interested volunteers were screened for eligibility with 
a full medical history, baseline spirometry and methacholine challenge and allergen skin 
testing. In order to determine eligibility for tetramer studies, HLA subtyping was performed 
on peripheral blood samples by the American Red Cross reference laboratories. Detailed 
inclusion and exclusion criteria as well as the study protocol are provided in the 
Supplementary Materials. Subjects gave their written informed voluntary consent before 
testing and sample collection. Eligible subjects underwent SAC with optical coherence 
tomography (OCT) imaging and collection of BAL fluid before and after allergen challenge 
for analysis. The study was approved by the Partners Healthcare Institutional Review Board.
Allergen Skin Testing
Standardized allergen extract for cat hair and Dermatophagoides pteronyssinus were 
purchased from Greer Laboratories. AA and AC had a positive skin prick test to either cat 
hair or dust mite extract while HC had negative skin tests to allergens. The threshold level of 
allergen sensitivity was determined by skin prick test titration using serial 3-fold dilutions of 
extract (12). The lowest concentration of extract eliciting a positive skin prick test (3 mm 
wheal diameter) was used as the allergen concentration for SAC in AA and AC subjects; for 
HC, 500 AU/ml of cat hair extract was administered.
Segmental Allergen Challenge
SAC was performed as previously described (9–11). Briefly, a pre-challenge 
bronchoalveolar lavage (BAL) was obtained from the lingula using 4 × 30 l aliquots of 
normal saline. Diluent (2 ml) was then administered to the anterior segment of the right 
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upper lobe followed by administration of allergen (2 ml) to the lateral segment of the right 
middle lob. Twenty-four hours later, BAL samples were obtained from the diluent and 
allergen-challenged lung segments.
Cytospins
Cell differential counts for BAL were determined by enumerating mononuclear cells, 
neutrophils, and eosinophils on cytocentrifuge preparations (9, 10).
Flow cytometry
BAL cells were stained with fluorescent-conjugated antibodies against CD3, CD4, CD8, 
CD25, CD45RA, CCR4, CRTH2, IL-33R, and IL-25R (Biolegend). Some cells were stained 
for Foxp3 (eBioscience). Phycoerythrin (PE)-conjugated MHC class II tetramers containing 
either house dust mite (Der p 1) or cat hair (Fel d 1) peptides (Supplementary Table 2) were 
prepared in our laboratory as previously described (35, 46, 47). Baseline and diluent samples 
underwent enrichment for tetramer positive cells with anti-PE micromeads and magnetic 
column selection (Miltenyi Biotec) as previously described (35, 46, 47). Samples were run 
on an LSRFortessa flow cytometer (BD Biosciences) and analyzed with FlowJo software 
(Tree Star).
Cytokine and chemokine analysis—Cytokines and chemokines were analyzed by 
Milliplex MAP kit (EMD Millipore) using 30-fold concentrated BAL supernatant. BAL was 
concentrated in Amicon Ultra-15 centrifugal filter units (EMD Millipore) and used in the kit 
according to the manufacturer’s instructions. Cytokines and chemokines were measured on a 
Luminex 200 and analyzed using xPONENT 3.1 software (Luminex Corp.).
Transcriptome analysis—BAL cells from the allergen-challenged segment were 
enriched for CD4+ T cells by negative selection using magnetic beads (StemCell 
Technologies). Cells were stained with CD4 and CD25, and CD4+CD25high Tregs were 
sorted to > 97% purity with a FACSAria II (BD Biosciences). RNA was purified with the 
RNeasy Plus Mini Kit (Qiagen). Global gene expression was profiled using a Human HT-12 
V4 Expression BeadChip according to manufacturer’s instructions (Illumina). Image 
analysis, bead-level processing and quantile normalization of array data were performed 
using the Illumina LIMS platform, BeadStudio. A gene-wise linear model was fitted to the 
data and was performed in R programming language (http://www.r-project.org/), utilizing 
functions from Linear Models for Microarray Data (48). For each probe, a moderated t-
statistic (with standard errors moderated across genes) was computed using a Bayesian 
model. For each transcript, log-transformed ratios were computed for the allergen segment 
relative to the baseline or diluent segment.
Mucin measurement—Total mucin concentration was measured in BAL samples using 
differential refractometry (tREX, Wyatt Technology) coupled with size exclusion 
chromatography as described previously (18).
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MUC5AC Assessment
BAL samples were prepared for analysis as previously described (49). Briefly, 250 μl BAL 
samples were denatured, reduced and alkylated. Samples were then buffer-exchanged into a 
pH 8.0 digestion buffer (50 mM ammonium bicarbonate) using a HiTrap Desalting column 
(GE Healthcare). Samples were digested with trypsin at 37°C overnight. The final digest was 
vacuum dried to remove bicarbonate salts. The digest peptides were re-solubilized in 20 μL 
0.1 % formic acid water or were stored −30 °C until liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) was run. The LC-MS/MS was performed with a Dionex 
UltiMate 3000 RSLCnano system coupled to a hybrid quadrupole orbitrap mass 
spectrometer with a Nano spray source (Q Exactive, Thermo Fisher Scientific). Peptides 
were analyzed by a data-dependent top 10 method dynamically choosing the most abundant 
precursor ions from the survey scan (300–1650 Th) for HCD fragmentation. Proteins 
identified from the BAL were quantified using a label-free method termed the normalized 
spectral index (SI(N)). SI(N) is defined as the cumulative fragment ion intensities for all 
spectra counted for a protein (50).
OCT Mucus Assessment
Mucus was automatically detected using custom image segmentation algorithms. The suite 
of algorithms used a two-step identification process. In the first step, the sheath and tissue 
lumen were identified. The second step looked for mucus in the region between sheath and 
tissue lumen using a combination of thresholding and intelligent exclusion of image artifact. 
All of the data was checked for accuracy and frames in which the mucus content was 
ambiguous were excluded. Mucus particulate content was assumed to be proportional to the 
scattering intensity of the mucus (21), and the average quantity of particulate content per 
dataset was equated to the mean pixel intensity for all mucus-identified pixels.
ASM measurement—ASM band width and thickness was assessed using OR-OCT as 
described (see Adams, D. et al. co-submission). Regions 6mm in length and of comparable 
radius (+/− 0.1 mm) were analyzed for both ASM thickness and band width. To compare the 
measured ASM thickness between datasets, the measured ASM area was normalized to the 
local basement membrane perimeter.
Statistical analysis—Data are expressed as mean ± SEM unless otherwise noted. Chi 
squared test or Fisher’s exact test was used to evaluate categorical values and the non-
parametric t test was used for continuous data. Median allergen doses were not normally 
distributed and thus, comparison was performed with the use of the Mann-Whitney test. 
Two-way ANOVA was used to compare mean differences between groups. Tukey’s or 
Sidak’s test was used to correct for multiple comparisons. Since the distribution was skewed, 
cytokine data were log transformed for analysis. Pearson correlation coefficients were used 
for assessing the strength of association between pairs of predefined variables. In all cases, 
differences in results were considered to be statistically significant when P was less than 
0.05 based on a two-sided test.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Airway cellular response after segmental allergen challenge (SAC)
(a) Percentages and numbers of eosinophils, neutrophils and mononuclear cells in BAL fluid 
at baseline and 24 hours following diluent or allergen exposure in AA (red) and AC (blue) 
subjects (n = 36 AA, n = 48 AC). Total cell counts are also shown (healthy controls (HC) 
shown in gray (n = 4)). (b) Percentage and number of CD8+ T cells and CD4+ T cells in the 
BAL (n = 31 AA, n = 44 AC). Percentage and number of Tregs in the BAL and ratio of 
Tregs to total CD4+ T cells (n = 22 AA, n = 23 AC). Bln, baseline; Dil, diluent, Ag, antigen. 
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by two-way ANOVA.
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Fig. 2. Phenotyping of Tregs
(a) Functional Treg subpopulations (green box) and a representative flow plot. I – naïve 
Tregs, II – suppressive Tregs, III – non-suppressive Tregs, IV effector and memory CD4+ T 
cells (Te+m) and V – naïve CD4+ T cells. (b) Percent and numbers of Treg subpopulations 
in AA (red squares) and AC (blue circles) subjects (n = 7 AA, n = 10 AC). *P < 0.05, **P < 
0.01, ***P < 0.001 by two-way ANOVA. (c) Ratio of suppressive Tregs (I and II) to Te+m 
cells (IV) (n = 7 AA, n = 10 AC). (d) Expression levels of 6 genes relevant for Treg function 
are shown from a genome-wide transcriptome microarray analysis performed on sorted cells 
obtained after SAC from AA (red bars) and AC (blue bars) subjects. Data are displayed as 
medians (bar), interquartile range (box; 25th to 75th percentiles), and minimum and 
maximum values (whiskers). Nominal P values were determined utilizing linear models for 
microarray (LIMMA).
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Fig 3. Phenotyping of allergen-specific CD4+ T cells
(a) Representative gating for tetramer+CD4+ T cells. (b) The percentage and number of 
tetramer+CD4+ T cells in the BAL for AA (red squares) and AC (blue circles) subjects (n = 
13 AA, n = 19 AC). (c) Representative gating for Th2 markers on bulk and tetramer+CD4+ T 
cells from an AA subject. (d) Percentage of tetramer+CD4+ (AA red squares, AC blue 
circles) or bulk CD4+ (AA red triangles, AC blue triangles) T cells expressing the Th2 
markers CCR4 (n = 11 AA, n = 16 AC), CRTH2 (n = 6 AA, n = 9 AC), IL-33R (n = 12 AA, 
n = 14 AC), and IL-25R (n = 5 AA, n = 7 AC). *P < 0.05, **P < 0.01, ***P < 0.001, ****P 
< 0.0001 by two-way ANOVA.
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Fig. 4. Th2 cytokine levels and correlations
(a) Protein levels of IL-4, IL-5, IL-9, IL-13 and CCL26 in BAL fluid (n = 32 AA, n = 41 
AC). Data are presented as median (bar), interquartile range (box; 25th to 75th percentiles) 
and minimum and maximum values (whiskers); cross denotes the mean. *P < 0.05, **P < 
0.01, ***P < 0.001, ****P < 0.0001 by two-way ANOVA. (b) Correlation between IL-4, 
IL-5, IL-9, IL-13 and CCL26 levels in BAL fluid and the percentage of eosinophils in the 
allergen segment (n = 32 AA, n = 41 AC). Pearson’s correlation, P < 0.0001 for all. AA 
shown in red squares, AC shown in blue circles). (c) Correlation between IL-4, IL-5, IL-9, 
IL-13 and CCL26 and percent IL-33R+ allergen-specific CD4+ T cells in the allergen 
segment (n = 10 AA, n = 13 AC). Pearson’s correlation, P < 0.001 for IL-13, P <0.01 for all 
others.
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Fig. 5. Characterization of airway mucus after SAC
(a) Total mucin in BAL fluid at baseline and after diluent and allergen exposure (n = 11 AA, 
n = 16 AC, n = 5 HC). (b) MUC5AC levels in BAL fluid at baseline and after diluent and 
allergen exposure (n = 9 AA, n = 11 AC). SI(N) = normalized spectral index. (c) 
Representative images of airway mucus using optical coherence tomography (OCT). Mucus 
is represented in yellow. *, catheter; L, airway lumen; scale bar 1 mm. pOCT = mean OCT 
intensity. (d) Correlation between pOCT intensity and total mucin measured by 
refractometry (n = 3 AA, n = 11 AC). Pearson’s correlation, P < 0.001). (e) pOCT intensity 
of airway mucus before and after SAC (n = 12 AA, n = 20 AC, n = 3 HC). (f) Correlation 
between pOCT intensity and levels of IL-4 and IL-13 in BAL fluid after allergen (n = 11 
AA, n = 17 AC). Pearson’s correlation, P < 0.05 for AA IL-4 and AA IL-13. For 5a–b and 
5d–f, AA shown in red squares, AC shown in blue circles, HC shown in gray triangles. For 
5a, 5b, and 5e *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by two-way ANOVA.
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Fig. 6. Characterization of airway smooth muscle
ASM measurements obtained using orientation-resolved OCT (OR-OCT). (a) Top panels are 
volumetric reconstructions from circularized data with ASM represented in terms of 
thickness (color) overlaid on airway structure (grayscale). Bottom panels are the same ASM 
data unrolled circumferentially and “flattened” for ASM quantification. Scale bars are 
corresponding 6 mm regions of comparable airway perimeter from each dataset where the 
ASM distribution was quantified. (b) Quantification of ASM thickness and band width (n = 
3 AA, n =3 AC, n= 3 HC). AA shown in red squares, AC shown in blue circles, HC shown 
in gray triangles. *P < 0.05 by two-way ANOVA.
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